Linezolid APOTEX

Pajjiż: New Zealand

Lingwa: Ingliż

Sors: Medsafe (Medicines Safety Authority)

Ingredjent attiv:

Linezolid 600mg

Disponibbli minn:

Apotex NZ Ltd

INN (Isem Internazzjonali):

Linezolid 600 mg

Dożaġġ:

600 mg

Għamla farmaċewtika:

Film coated tablet

Kompożizzjoni:

Active: Linezolid 600mg Excipient: Colloidal silicon dioxide Crospovidone Hyprolose Hypromellose Macrogol 8000 Magnesium stearate Methylcellulose Titanium dioxide

Tip ta 'preskrizzjoni:

Prescription

Manifatturat minn:

Apotex Pharmachem India Pvt. Ltd.

Indikazzjonijiet terapewtiċi:

Linezolid APOTEX is indicated for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: · Pneumonia - community acquired and nosocomial pneumonia · Skin and soft tissue infections · Enterococcal infections. Linezolid is active against Gram-positive bacteria only. Linezolid has no clinical activity against Gram-negative pathogens. Specific Gram-negative therapy is required if a concomitant Gram-negative pathogen is documented or suspected. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Sommarju tal-prodott:

Package - Contents - Shelf Life: Blister pack, white opaque PVC film/Aluminium - 10 tablets - 12 months from date of manufacture stored at or below 30°C protect from light

Data ta 'l-awtorizzazzjoni:

2014-03-28